Fig. 5

sCLU facilitated cancer stem cell properties of HCC via AKT/GSK-3β/β-catenin Axis. a, b MTT assay was used to detect the viability of HCCLM3 cells transfected with NC or sh-sCLU after sorafenib or doxorubicin treatment with or without LiCl exposure. c, d The viability of HepG2 cells transfected with NC or sh-sCLU after sorafenib or doxorubicin treatment with or without LY294002 exposure. e The colony formation of HCCLM3 cells after sorafenib or doxorubicin treatment with or without LiCl exposure. f The relative colony number in e. g The colony formation of HepG2 cells after sorafenib or doxorubicin treatment with or without LY294002 exposure. h The relative colony number in g. i, k The relative migration and invasion of sCLU-repressed HCCLM3 cells with or without LiCl treatment. j, l The relative migration and invasion of sCLU-overexpressed HepG2 cells with or without LY294002 treatment. m The tumor spheroids derived from sCLU-repressed HCCLM3 cells with or without LiCl treatment. n Relative spheroid size in m. o The tumor spheroids derived from sCLU-overexpressed HepG2 cells with or without LY294002 treatment. p Relative spheroid size in o. **P < 0.01